Tirzepatide vs. semaglutide: what the trials actually show

What did @chaseveryday actually say?

The creator walked through a side-by-side comparison of semaglutide and tirzepatide, explaining that both are GLP-1 agonists but that tirzepatide adds a GIP component that "targets insulin resistance in particular." They cited a head-to-head study showing tirzepatide produced greater weight loss, noted tirzepatide tends to cause less nausea, and acknowledged semaglutide is typically cheaper. They closed by recommending viewers consult a provider.

This is a reasonably structured comparison for a short-form video. The creator is not a clinician but is framing a personal experience while directing viewers toward professional consultation. That context matters when evaluating the claims below. The mispronunciations of both drug names throughout the video are minor issues, but they do signal a lay-level familiarity with the science rather than clinical expertise.

Does the science back this up?

Mostly, yes. The core comparison holds up well against published trial data, though a few details are oversimplified in ways that could mislead viewers.

The head-to-head study the creator references is almost certainly the SURMOUNT-5 trial (Jastreboff et al., 2025, New England Journal of Medicine), which directly compared tirzepatide and semaglutide 2.4 mg in adults with obesity. Tirzepatide produced roughly 20.2% mean body weight reduction versus 13.7% for semaglutide over 72 weeks. That is a real and statistically significant difference, so the creator's claim checks out.

The GIP mechanism explanation is broadly accurate. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Research suggests GIP receptor activation contributes to improved insulin sensitivity and may enhance fat metabolism (Frias et al., 2021, New England Journal of Medicine). Calling it "another mark of defense" for insulin resistance is a simplified but not wrong framing.

What did they get wrong (or right)?

The nausea claim deserves scrutiny. The creator says tirzepatide has "fewer negative side effects, one of them being nausea." This is partially supported but overstated. SURMOUNT-5 data does show a somewhat lower rate of nausea with tirzepatide compared to semaglutide at their respective maximum doses, but both drugs share a very similar gastrointestinal side effect profile. Vomiting, diarrhea, and constipation occur with tirzepatide too. Framing tirzepatide as broadly having fewer side effects could give viewers unrealistic expectations.

The GLP-1 mechanism description, that the medication "binds to the GLP1 in our bodies and helps them work more properly," is a loose but not dangerously wrong lay explanation. GLP-1 receptor agonists mimic endogenous GLP-1, they do not strictly supplement a deficiency in most users. People with obesity do not necessarily have low GLP-1 levels. The "fills in the gap" framing is more poetic than precise.

What the creator got right: the price differential is real. Brand-name tirzepatide (Zepbound) generally carries a higher list price than semaglutide (Wegovy), and that is a legitimate consideration for patients.

What should you actually know?

If you are weighing these two medications, a few things the video did not cover are worth knowing before you talk to a provider.

• SURMOUNT-5 compared maximum approved doses of each drug. Most patients do not reach or tolerate maximum doses, so real-world differences in weight loss may be smaller than the headline trial numbers suggest.
• Neither medication is a cure for obesity. Both require ongoing use to maintain results. Weight regain after discontinuation has been documented in multiple trials (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
• Tirzepatide is FDA-approved for weight management under the brand name Zepbound and for type 2 diabetes as Mounjaro. Semaglutide is approved for weight management as Wegovy and for type 2 diabetes as Ozempic. Compounded versions of either drug are not equivalent to FDA-approved branded formulations and carry different regulatory and quality considerations.
• Side effect profiles overlap substantially. Both drugs carry a boxed warning regarding a potential risk of thyroid C-cell tumors observed in rodent studies. Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
• Cost and insurance coverage vary widely. Out-of-pocket costs can run several hundred to over a thousand dollars per month depending on insurance status and whether a patient qualifies for manufacturer savings programs.

Bottom line

This video is more accurate than most GLP-1 content circulating on TikTok. The creator cites a real trial, gets the dual-agonist mechanism directionally right, and repeatedly tells viewers to consult a provider. The nausea comparison is oversimplified and the mechanism explanation is imprecise, but neither rises to the level of misinformation. The bigger gap is what was left out: medication duration dependency, compounding risks, and the nuance that superior trial results at maximum dose do not automatically mean better results for every individual patient.